A targeted pill compared with chemotherapy for slow growing brain tumors in young people
Original title: Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study that is still testing whether the drug helps.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a daily targeted pill against standard chemotherapy in young people with a slow growing brain tumor.
Who this trial is for. This trial is for children, teens, and young adults with a slow growing brain or spine tumor. It is for tumors that are not linked to NF1 and do not have a BRAFv600 gene change. It compares a daily pill, trametinib, with weekly vinblastine chemotherapy.
Where it stands. The trial has not reported results. It is measuring how long the tumor stays stable over 3 years in each group. It also tracks how tumors respond, side effects, and quality of life. The answer is not in yet.
What this means, and what it doesn't
What it could mean: A family whose child fits this picture may want to ask their care team about it. The care team can explain what joining would involve. They can also say if it looks like a fit.
What it doesn't mean: This does not mean the pill works better than chemotherapy. A trial is a test, not a proven treatment. Being in one is not a guarantee that it will help. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.